Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 760 Parkside Ave #321, Brooklyn, NY 11226, USA
- Website
- xylyxbio.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Endomimetics, Inc. | Birmingham, AL | — |
| Insphero, Inc. | Portland, ME | 325414 Biological Product (except Diagnostic) Manufacturing |
| Lena Biosciences, Inc. | Atlanta, GA | — |
| Plurexa LLC | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mimetas US Inc. | Gaithersburg, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Xylyx Bio, Inc. is a corporate entity registered in SAM.gov since July 2017, specializing in advanced bioengineering and tissue modeling technologies with a focus on developing innovative cell-based research platforms for medical research and drug development. The company is a for-profit organization located in Brooklyn, New York, that appears to be developing sophisticated bioengineered tissue models and platforms to address critical challenges in medical research, particularly in areas of organ transplantation, disease modeling, and drug discovery.
Through its federal grant awards, Xylyx Bio, Inc. has received multiple Small Business Innovation Research (SBIR) grants from prominent National Institutes of Health agencies, including the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Diabetes and Digestive and Kidney Diseases. These grants have supported the development of highly specialized cell-based assay platforms for modeling complex medical conditions, such as lung fibrosis, liver fibrosis, and metastatic breast cancer. Specifically, the company has been developing innovative research platforms that integrate patient-derived cells with human extracellular matrix (ECM) to create physiologically-relevant in-vitro models. These platforms aim to improve drug testing and development by providing more accurate representations of disease environments, addressing significant gaps in current research methodologies. Notable projects include creating bioengineered human lung grafts, developing multi-organ metastatic breast cancer models, and generating liver fibrosis cell-based assay platforms that can potentially accelerate anti-fibrotic and anti-metastatic drug development.
Quick answers
Is Xylyx Bio, Inc. registered in SAM.gov?
Yes. Xylyx Bio, Inc.'s SAM.gov registration is active through March 23, 2027.
What is Xylyx Bio, Inc.'s CAGE code?
Xylyx Bio, Inc.'s CAGE code is 7ZP58, and its Unique Entity ID (UEI) is N2N9KL2Y52X1.
What is Xylyx Bio, Inc.'s most recent federal award?
Xylyx Bio, Inc.'s most recent federal grant award is Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation (R44HL182545), from National Heart Lung and Blood Institute (NIH), on September 8, 2025.
On GovTribe
See Xylyx Bio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors